Back to search
FDAFDA · Food and drugs·Recall number Z-1480-2024

Alinity i Anti-HCV Reagent Kit, List Number 08P0521

Published April 10, 2024 · Recall initiated: March 4, 2024

Summary

FDA records medical device Class II recall Z-1480-2024, published April 10, 2024 and initiated March 4, 2024. Recalling firm: Abbott GmbH; Status: Ongoing; Reported quantity: 5110 units; Lot: UDI/DI 00380740130657, Lot Numbers: 52020BE00, 54149BE00, 56384BE00, 58172BE00, 59203BE00. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Customer complaints were received regarding falsely elevated results for some patient samples. Internal studies with customer return samples confirmed potential interactions that may lead to falsely elevated results when processed as below on the same instrument: " ARCHITECT Syphilis TP (LN 8D06) and/or ARCHITECT AdviseDx SARS-CoV-2-IgG II (LN 6S60) precedes ARCHITECT Anti-HCV testing (LN 1L79). " Alinity i Syphilis TP (LN 07P60) precedes Alinity i Anti-HCV testing (LN 08P05).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Abbott GmbH
Distributor
US Nationwide distribution.
Lot
UDI/DI 00380740130657, Lot Numbers: 52020BE00, 54149BE00, 56384BE00, 58172BE00, 59203BE00
Risk classification
Class II
Area (FDA)
device
Country
Germany

Related recalls

Questions about this recall

Was Alinity i Anti-HCV Reagent Kit, List Number 08P0521 recalled?

Yes. FDA published recall Z-1480-2024 on April 10, 2024. Reported hazard: Customer complaints were received regarding falsely elevated results for some patient samples. Internal studies with customer return samples confirmed potential interactions that may lead to falsely elevated results when processed as below on the same instrument: " ARCHITECT Syphilis TP (LN 8D06) and/or ARCHITECT AdviseDx SARS-CoV-2-IgG II (LN 6S60) precedes ARCHITECT Anti-HCV testing (LN 1L79). " Alinity i Syphilis TP (LN 07P60) precedes Alinity i Anti-HCV testing (LN 08P05).

What should I do if I have this product?

Voluntary: Firm initiated · Letter